• Viewed 10,240 times by 3014 users (Last 30 days)
  • print Created with Sketch. Print
ATX
Click for more information
0.00% 6.2¢

AMPLIA THERAPEUTICS LIMITED - Charts / Financials

Market Cap $12.02M  ! watchlist Created with Sketch. Add to my watchlist
Healthcare Biotechnology

Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development... Amplia Therapeutics Limited is an Australia-based clinical-stage, drug development company. The Company is focused on developing proprietary, orally available, small molecule Focal Adhesion Kinase (FAK) inhibitors as candidate drugs for the treatment of cancer and various fibrotic diseases. The Company’s pipeline includes AMP945 and AMP886. AMP945 is a selective and potent inhibitor of FAK and is in clinical development for pancreatic cancer and advanced preclinical development for idiopathic pulmonary fibrosis (IPF). The Company’s second pipeline drug, AMP886, inhibits FAK and inhibits two key disease drug targets (VEGFR3 and FLT3). This drug is being evaluated in preclinical models of cancer. Its fibrosis program uses its FAK inhibitors to block fibrosis and cell migration in cancers. Its cancer Program is directed at using its FAK inhibitors to block FAK activity in the cancer cells and the surrounding tissue and therefore block survival/proliferation signals.More

Corporate Spotlight
Not Yet Available

Are you a Company Director ?
Put your Investment Case to Hotcopper's 700K monthly unique visitors.

Claim your IR profile arrow Created with Sketch.
See benefits
refresh Created with Sketch. REFRESH
Last update - 16.20pm 03/05/2024 (20 minute delay) ?
Day
Open 0.0¢   Day High 0.0¢   Day Low 0.0¢
Daily Volume 0
Bids   Sellers
Number Price Volume   Number Price Volume
1 6.1¢ 150000   2 6.2¢ 180369

Directors & Senior Management

Dr. Christopher John Burns Chief Executive Officer, Managing Director, Director
Mr. Hamish George Chief Financial Officer
Dr. Mark Devlin Chief Scientific Officer
Mr. Andrew John Cooke Company Secretary
Mr. Warwick Bonner Tong Non-Executive Independent Chairman of the Board
Mrs. Jane Bell Non-Executive Independent Director
Dr. Robert Peach Non-Executive Independent Director

Data source: Refinitiv

(20min delay)
Last
6.2¢ 		Change
0.000(0.00%) 		Mkt cap ! $12.02M
Open High Low Value Volume
0.0¢ 0.0¢ 0.0¢ $0 0

Buyers (Bids)

No. Vol. Price($)
1 150000 6.1¢
 

Sellers (Offers)

Price($) Vol. No.
6.2¢ 180369 2
View Market Depth
Last trade - 16.12pm 03/05/2024 (20 minute delay) ?

Top Stories

Infini Resources gearing up for UAV geophys survey over Portland Creek

Infini Resources has announced its execution of an application for UAV-based geophysical surveys over its Portland Creek Uranium Project.
Lithium Universe ends the quarter charged up for Quebec Refinery roll-out Lithium Universe has closed off the March quarter with a new Chief Financial Officer and strategically located land anchored for its lithium refinery in Quebec, Canada.
Patagonia shares rise above 20% on lithium grades at maiden well in Argentina Patagonia Lithium shares rise above 12 percent on lithium grading nearly 600 parts per million at the first drill well of its Argentinian Formentera Lithium Project.
Macquarie profits fall 32% on 'market volatility' and low-achieving 'green investments' Macquarie Group Ltd (ASX:MQG) has shaved more than 30 percent off its net profit in the final quarter of the 2024 financial year (FY 2024), compared to the same time last year, with executives speaking cautiously about market volatility and @lower asset realisations’ from green in...
Car EV-olution accelerates Oz into pole position As the world steers towards a more sustainable future, the surge in electric vehicle (EV) sales is turning industries upside down, and mining is no exception. Australia, famous for its treasure trove of minerals, finds itself right in the middle of this shift, which raises two questions. Firstly,...
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.